Eloxx Pharmaceuticals has dosed the first two patients in its Phase 2b EXACT study testing exaluren for nonsense mutation Alport syndrome (NMAS), a rare genetic kidney disease with no FDA-approved treatments. The trial will evaluate the drug's safety and efficacy in 24 patients, with topline data from the initial 16-week placebo-controlled phase expected by mid-2027 and final results by the end of 2027. Exaluren aims to address the genetic cause by promoting production of functional protein, offering hope for patients who often face kidney failure by their twenties.
Ipsos posted €636.2 million revenue in Q3 2026 with 2.0% organic growth, up from 0.8% in H1, led by strong performances in EMEA, China, and its Citizens business. The company updated its full-year organic growth outlook to 1.2%-1.5%, citing ongoing g...
Ipsos achieved 2.0% organic revenue growth in Q3 2026, up from 0.8% in H1, driven by strong performances in EMEA, China, and citizen-related activities. The company updated its 2026 organic growth target to 1.2%-1.5%, reflecting improved momentum and...
Signify reported third-quarter 2026 results with sales of EUR 1,367 million, a slight decline in comparable sales by 3.4%, but improved adjusted EBITA of EUR 145 million and a margin increase to 10.6%. Net income rose to EUR 88 million and free cash ...
Volvo Cars announced plans to cut 2,500 jobs following a sharp decline in earnings for the third quarter. The company reported an operating loss of 5.6 billion Swedish Kronor ($563.7 million), a significant drop from a 6.4 billion Kronor profit in th...
U.S. Bitcoin investment funds experienced $635.49 million in net withdrawals on Thursday, ending three days of inflows. Major funds like BlackRock's iShares Bitcoin Trust and Fidelity's Wise Origin Bitcoin Fund accounted for about 74% of the outflows...
